Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
- PMID: 12201938
- DOI: 10.1080/003655902320131901
Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Abstract
Objectives: Urine cytology is the gold standard in the diagnosis and follow-up of bladder cancer. Cytology, however, exhibits variable sensitivity depending on tumour grade and interpretation of urine specimens is highly dependent on the skill of the examiner. Positive cytology, classes IV and V by Papanicolaou classification, is a strong predictor for coexisting or subsequent malignancy, while the role of suspicious cytology, class III, is controversial. The objective of the study was to evaluate the role of the suspicious finding in cytological analysis, and whether it should be considered as a negative or positive sign for coexisting malignancy.
Material and methods: Six hundred and fifty-two consecutive patients with bladder cancer were studied in a prospective multicenter trial. One hundred and fifty-one of the patients were newly diagnosed, and the remaining 501 patients were under follow-up. A voided urine sample was obtained prior to TURB or prior to routine follow-up cystoscopy in those under the surveillance and split for culture and cytology. The cytopathological results were analyzed by a central review and only patients with samples available for review analysis were included. Sensitivity and specificity, as well as positive (PPV) and negative (NPV) predictive values of urine cytology were calculated by classifying the class III samples as negative or positive.
Results: A total of 570 patients were evaluable. One hundred and twenty nine (22.6%) were newly diagnosed and 441 were under follow-up, of whom 117 (26.5%) had recurrence. Cytology was classified as suspicious in 33/129 (25.6%) patients with primary tumour, and in 41/441 (9.3%) of those under the follow-up, of whom 20 (48.8%) had recurrence. Sensitivity increased from to 31.0% to 56.6% in primary tumours (p < 0.001) and from 17.8% to 34.7% in recurrent tumours (p < 0.001) if class III was determined as positive, whereas the specificity decreased from 96.6% to 90.1% (p < 0.001). Accordingly, the NPV increased from 76.3% to 79.1% and the PPV decreased from 65.6% to 56.2%.
Conclusions: The poor sensitivity of voided urine cytology improved significantly when suspicious samples were determined as positive while the specificity remained high, a clear advantage compared with most of the new tumour marker tests. In addition, nearly half of the follow-up patients with suspicious class III cytology had recurrence implying that this patient category is at substantial risk for co-existing malignancy. Therefore, it is recommended that suspicious class III cytology together with class IV and V specimens should be considered positive.
Similar articles
-
The dilemma of suspicious urine cytology in patients being followed for bladder cancer.Ann Chir Gynaecol. 2001;90(4):256-9. Ann Chir Gynaecol. 2001. PMID: 11820413
-
Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.Ann Chir Gynaecol. 2001;90(4):261-5. Ann Chir Gynaecol. 2001. PMID: 11820414
-
Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.Eur Urol. 2007 May;51(5):1267-74. doi: 10.1016/j.eururo.2006.12.019. Epub 2006 Dec 18. Eur Urol. 2007. PMID: 17207912
-
The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients.J Urol. 1997 Jun;157(6):2112-4. J Urol. 1997. PMID: 9146593 Review.
-
[Cytology in urine obtained by spontaneous miction. Its usefulness in follow-up of tumors of the bladder].Actas Urol Esp. 1989 Jan-Feb;13(1):32-5. Actas Urol Esp. 1989. PMID: 2652994 Review. Spanish.
Cited by
-
Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.BJU Int. 2014 Sep;114(3):354-9. doi: 10.1111/bju.12516. Epub 2014 Feb 14. BJU Int. 2014. PMID: 24128299 Free PMC article.
-
Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report.SAGE Open Med Case Rep. 2020 Jun 13;8:2050313X20932694. doi: 10.1177/2050313X20932694. eCollection 2020. SAGE Open Med Case Rep. 2020. PMID: 32587697 Free PMC article.
-
Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up?J Clin Pathol. 2004 Apr;57(4):365-8. doi: 10.1136/jcp.2003.009696. J Clin Pathol. 2004. PMID: 15047737 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical